GIM
ORMP icon

Greylin Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Greylin Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,900
Closed -$415K – 93
2021
Q3 		$415K Buy
+18,900
New +$322K 0.09% 69
2016
Q2 		– Sell
-10,300
Closed -$69K – 71
2016
Q1 		$69K Sell
10,300
-4,850
-32% -$32.5K 0.02% 69
2015
Q4 		$130K Sell
15,150
-7,650
-34% -$58K 0.03% 74
2015
Q3 		$125K Sell
22,800
-22,300
-49% -$140K 0.03% 57
2015
Q2 		$256K Sell
45,100
-4,900
-10% -$33.5K 0.06% 51
2015
Q1 		$228K Hold
50,000
– – 0.05% 57
2014
Q4 		$228K Sell
50,000
-39,500
-44% -$260K 0.05% 57
2014
Q3 		$728K Sell
89,500
-1,700
-2% -$15.1K 0.17% 39
2014
Q2 		$877K Buy
91,200
+6,300
+7% +$64.3K 0.21% 34
2014
Q1 		$1M Buy
84,900
+33,200
+64% +$560K 0.24% 33
2013
Q4 		$798K Buy
+51,700
New +$398K 0.2% 41

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Greylin Investment Management's ORMP Position: Q4 2021 in Review

Greylin Investment Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 18,900 shares — an estimated $415K sold.

Greylin Investment Management first reported a position in ORMP in Q4 2013 and held it in 11 quarters. The position peaked at $1M in Q1 2014. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

  • Greylin Investment Management reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Greylin Investment Management sold 18,900 Oramed Pharmaceuticals shares in Q4 2021, an estimated $415K.
  • Greylin Investment Management first reported a position in Oramed Pharmaceuticals in Q4 2013 and held it in 11 quarters.
  • Greylin Investment Management's Oramed Pharmaceuticals position peaked at $1M in Q1 2014.
  • 116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Greylin Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.